{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:53:47Z","timestamp":1790254427054,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jval.2018.07.878","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T08:44:55Z","timestamp":1535705095000},"page":"254-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Economic Evaluation of Stem Cell Therapies in Neurological Diseases: A Systematic Review"],"prefix":"10.1016","volume":"22","author":[{"given":"Anjali","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Milte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Hamilton-Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Koblar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.07.878_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Ahmad Kiadaliri","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2018.07.878_bib2","first-page":"e259","article-title":"Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990\u20132010: findings from the Global Burden of Disease Study 2010. Lancet","volume":"1","author":"Krishnamurthi","year":"2013","journal-title":"Glob Health"},{"key":"10.1016\/j.jval.2018.07.878_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jval.2018.07.878_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jval.2018.07.878_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/ten.teb.2016.0291","article-title":"Evaluating the past, present, and future of regenerative medicine: a global view","volume":"23","author":"Ronfard","year":"2017","journal-title":"Tissue Eng Part B Rev"},{"key":"10.1016\/j.jval.2018.07.878_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13287-017-0643-x","article-title":"Safety and effectiveness of stem cell therapies in early-phase clinical trials in stroke: a systematic review and meta-analysis","volume":"8","author":"Nagpal","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jval.2018.07.878_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6118\/jmm.2017.23.1.1","article-title":"Cell therapy products in Alzheimer disease","volume":"23","author":"Song","year":"2017","journal-title":"J\u00a0Menopausal Med"},{"key":"10.1016\/j.jval.2018.07.878_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","article-title":"Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era","volume":"21","author":"Barker","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jval.2018.07.878_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40263-017-0429-9","article-title":"Cell therapy for multiple sclerosis","volume":"31","author":"Sarkar","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jval.2018.07.878_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12916-017-0818-4","article-title":"Innovative regenerative medicines in the EU: A better future in evidence?","volume":"15","author":"Corbett","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2018.07.878_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/rme-2015-0046","article-title":"Opening the gateways to market and adoption of regenerative medicine? The UK case in context","volume":"11","author":"Faulkner","year":"2016","journal-title":"Regen Med"},{"key":"10.1016\/j.jval.2018.07.878_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/humc.2016.093","article-title":"Translation and reimbursement: the twin challenges for cell and gene therapies reflections of an ex-regulator","volume":"27","author":"Narayanan","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.jval.2018.07.878_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2217\/rme.13.69","article-title":"Early evaluation and value-based pricing of regenerative medicine technologies","volume":"8","author":"Koerber","year":"2013","journal-title":"Regen Med"},{"key":"10.1016\/j.jval.2018.07.878_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11593380-000000000-00000","article-title":"Early assessment of medical technologies to inform product development and market access","volume":"9","author":"Ijzerman","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2018.07.878_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2018.07.878_bib16","unstructured":"Nagpal A, Milte R, Kim SW, et\u00a0al. Economic evaluation of stem cell therapies in neurological diseases: a systematic review. Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42017072937. [Accessed February 12, 2018]."},{"key":"10.1016\/j.jval.2018.07.878_bib17","unstructured":"Covidence. Economic evaluation of stem cell therapies in neurological diseases: a systematic review. Available from: https:\/\/www.covidence.org\/reviews\/25747. [Accessed February 12, 2018]."},{"key":"10.1016\/j.jval.2018.07.878_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.07.878_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","article-title":"A\u00a0web-based tool for adjusting costs to a specific target currency and price year","volume":"6","author":"Shemilt","year":"2010","journal-title":"Evid Policy"},{"key":"10.1016\/j.jval.2018.07.878_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000337765","article-title":"Societal value of stem\u00a0cell\u00a0therapy in stroke\u2014a modeling study","volume":"33","author":"Svensson","year":"2012","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jval.2018.07.878_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.parkreldis.2006.04.006","article-title":"Estimating the value of novel interventions for Parkinson\u2019s disease: an early decision-making model with application to dopamine cell replacement","volume":"12","author":"Hjelmgren","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jval.2018.07.878_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bmt.2009.305","article-title":"Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis","volume":"45","author":"Tappenden","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jval.2018.07.878_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2018.07.878_bib24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","article-title":"Dyskinesias following neural transplantation in Parkinson\u2019s disease","volume":"5","author":"Hagell","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jval.2018.07.878_bib25","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1161\/STROKEAHA.109.557256","article-title":"Reliability of the modified Rankin Scale: a systematic review","volume":"40","author":"Quinn","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jval.2018.07.878_bib26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.39456.688333.BE","article-title":"Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies","volume":"336","author":"Slot","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2018.07.878_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","article-title":"Stem cell therapies in clinical trials: progress and challenges","volume":"17","author":"Trounson","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jval.2018.07.878_bib28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","article-title":"Dyskinesias following neural transplantation in Parkinson\u2019s disease","volume":"5","author":"Hagell","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jval.2018.07.878_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","article-title":"The EQ-5D\u2014a generic quality of life measure\u2014is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease","volume":"69","author":"Schrag","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jval.2018.07.878_bib30","first-page":"341","article-title":"Mapping the modified Rankin Scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome","volume":"30","author":"Oliver","year":"2009","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2018.07.878_bib31","article-title":"Lyon Clinique de Neurologie MS Registry","author":"Confavreux","year":"2008","journal-title":"Data held on file"},{"key":"10.1016\/j.jval.2018.07.878_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(08)70138-8","article-title":"Autologous haematopoietic stem-cell transplantation in multiple sclerosis","volume":"7","author":"Mancardi","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jval.2018.07.878_bib33","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2018.07.878_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson\u2019s disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.jval.2018.07.878_bib35","first-page":"525","article-title":"US cost burden of ischemic stroke: a systematic literature review","volume":"16","author":"Demaerschalk","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2018.07.878_bib36","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/rme.15.51","article-title":"Bringing regenerative medicines to the clinic: the future for regulation and reimbursement","volume":"10","author":"Bubela","year":"2015","journal-title":"Regen Med"},{"key":"10.1016\/j.jval.2018.07.878_bib37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","article-title":"Emerging use of early health technology assessment in medical product development: a scoping review of the literature","volume":"35","author":"Ijzerman","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.07.878_bib38","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1017\/S0266462308080616","article-title":"Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review","volume":"24","author":"Hartz","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2018.07.878_bib39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/sctm.16-0487","article-title":"Concise review: the high cost of high tech medicine: planning ahead for market access","volume":"6","author":"Driscoll","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jval.2018.07.878_bib40","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10072-016-2564-3","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience","volume":"37","author":"Curr\u00f2","year":"2016","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jval.2018.07.878_bib41","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518332352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:15:12Z","timestamp":1761095712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518332352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1098301518332352"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.07.878","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Stem Cell Therapies in Neurological Diseases: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.07.878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}